Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update.
Clinical data show that a 1% increase in serum concentrations of high-density lipoprotein cholesterol (HDL-C) can decrease cardiovascular risk by 2% to 3%. Therefore, mechanisms affecting the level and functionality of high-density lipoprotein (HDL) and its constituents are being investigated as targets for the rational development of drugs to prevent or treat cardiovascular disease. High-density lipoprotein-related research may also increase our understanding of the link between atherosclerosis and metabolic disorders. This report and update of the HDL Working Group discusses HDL metabolism and reverse cholesterol transport, impaired HDL as a marker and a cause of proatherogenic states, and experimental and current approaches to HDL-related therapy.
Weill Medical College of Cornell University, New York, New York 10021, USA. pat2004@med.cornell.edu
Antonio M
AM
Gotto
Eliot A
EA
Brinton
D001161:Arteriosclerosis / Q000097:blood; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D012307:Risk Factors
D015415:Biomarkers; D008076:Cholesterol, HDL